semaglutide therapy FDA Approves Oral for Weight Loss Semaglutide: Double-edged Sword with Risks

A healthy microbiome is essential for digestive health and overall well-being

Under optimized conditions, the engineered strain accumulated 15.3 g/L of riboflavin in 72 h, which is comparable to the B

Regor Therapeutics RGT-075 RGT-075 is a once-daily oral small-molecule GLP-1 receptor full agonist being developed by Regor for the treatment of metabolic disorders such as type 2 diabetes mellitus, obesity, and overweight conditions linked with weight-related comorbidities

Gut Health Gut health and immune response go hand in hand, and current research suggests that BPC-157 could be part of a treatment plan for several gastrointestinal issues, including leaky gut syndrome and irritable bowel disease